A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia

Wang, Yaoyao; Yang, Xiancong; Liu, Yalin; Li, You-jie

doi:10.3389/fimmu.2025.1505247

REVIEW article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1505247

A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia

Provisionally accepted

Yaoyao Wang ¹

Xiancong Yang ²

Yalin Liu ¹

You-jie Li ^1*

¹ Binzhou Medical University, Binzhou, China
² Qilu hospital of Shandong University dezhou hospital, Dezhou, China

The final, formatted version of the article will be published soon.

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy. Traditional chemotherapy methods not only bring serious side effects, but also lead to high recurrence rate and drug resistance in some patients. However, as an emerging therapeutic strategy, immunotherapy has shown great potential in the field of AML treatment in recent years. At present, common immunotherapy methods for AML include monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors. With the deepening of research and technological progress, especially the application of nanotechnology in medicine, new immunotherapy is expected to become one of the important means for the treatment of acute myeloid leukemia in the future.

Keywords: Acute Myeloid Leukemia, Antibody therapy, CAR-T cell therapy, immune checkpoint inhibitors, nanoimmunotherapy

Received: 02 Oct 2024; Accepted: 24 Feb 2025.

Copyright: © 2025 Wang, Yang, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: You-jie Li, Binzhou Medical University, Binzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.